Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Milan 20133

0 studies enrolling now · 3 studies all time

What they study most

Adjuvant, EGFR, Early Stage Lung Cancer, Exon 20, Low-grade Glioma, Lung Cancer, NSCLC, Stage IB-IIIA, Neuroblastoma, Pediatric Low-grade Glioma, Post-surgical, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Uncommon EGFR Mutations

Studies at this site

• Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) — Running, not enrolling